{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:21:57Z","timestamp":1792963317928,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>OnabotulinumtoxinA (onabotA) is indicated for upper facial lines (UFL). Fear of unnatural\u2010looking outcomes is a frequently reported treatment barrier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Examine patient\u2010reported outcomes (PROs) after onabotA treatment for UFL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post hoc analysis was conducted on two 12\u2010month pivotal studies of onabotA for forehead and glabellar lines (20\u2009U each), with\/without treatment of crow's feet lines (\u00b124\u2009U). This analysis used PROs from the Facial Line Satisfaction Questionnaire: Items 4 (natural look), 5 (treatment effect), 11 (met expectations), and Impact Domain (appearance and psychological impact). The analysis included 458 neurotoxin\u2010naive adults achieving a \u22652\u2010grade improvement in forehead line (FHL) severity on the Facial Wrinkle Scale at Day 30 (primary endpoint). [Corrections made on 28 December 2023, after first online publication: \u2018UFL\u2019 in the previous sentence has been corrected to \u2018forehead line (FHL)\u2019 in this version.] Data were further stratified into millennials and men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At Day 30, 90.5% of all participants, 94.6% of millennials, and 85.7% of men were satisfied with receiving a natural look. Millennials had higher odds of being satisfied with natural outcomes at Day 30. This measure remained &gt;\u200980% for all groups throughout the 12\u2009months. Additionally, \u226580% were satisfied with the treatment effect, and &gt;90% reported results met expectations. At Day 30, \u226550% reported positive impacts on self\u2010perceived appearance and psychological well\u2010being, but millennials had higher, and men had lower odds of reporting these improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants achieving a \u22652\u2010grade improvement in FHL severity after onabotA reported high satisfaction with natural outcomes and the treatment effect, with improved self\u2010perceived appearance and psychological well\u2010being. [Corrections made on 28 December 2023, after first online publication: \u2018UFL\u2019 in the previous sentence has been corrected to \u2018FHL\u2019 in this version.] These results may help aesthetic providers and patients address fears regarding unnatural results with onabotA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.15947","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T14:08:10Z","timestamp":1692886090000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Self\u2010perception of natural outcome, appearance, and emotional well\u2010being after OnabotulinumtoxinA treatment for upper facial lines: Post hoc analysis across age and gender"],"prefix":"10.1111","volume":"23","author":[{"given":"Steven","family":"Dayan","sequence":"first","affiliation":[{"name":"Denova Research  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Skin Concept  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Boyd","sequence":"additional","affiliation":[{"name":"BOYD  Birmingham Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"De\u00a0Boulle","sequence":"additional","affiliation":[{"name":"Aalst Dermatology Clinic  Aalst Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cavallini","sequence":"additional","affiliation":[{"name":"Unit of Dermatology and Dermatosurgery, Centro Diagnostico Italiano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"2020 Plastic Surgery Statistics Report.American Society of Plastic Surgeons.2022.https:\/\/www.plasticsurgery.org\/documents\/News\/Statistics\/2020\/plastic\u2010surgery\u2010statistics\u2010full\u2010report\u20102020.pdf"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.2022.6425"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab015"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000000876"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab358"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12128"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17429590701523927"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000475758.63709.23"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2357"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000001414"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000001612"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000002153"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12166"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000000424"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000002216"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000002047"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/gox.0000000000002669"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000000357"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac157"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab114"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojab036"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-015-0454-3"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.2020.4641"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac253"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31206"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T20:37:22Z","timestamp":1707424642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/jocd.15947"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15947","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}